[Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
暂无分享,去创建一个
[1] Mi-Jung Kim,et al. Diagnostic Utility of Galectin-3 in Aspirates of Thyroid Follicular Lesions , 2006, Acta Cytologica.
[2] J. Collet,et al. Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples , 2005, British Journal of Cancer.
[3] K. Metze,et al. Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy , 2005, Histopathology.
[4] A. Miyauchi,et al. Galectin‐3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma , 2005, Pathology.
[5] L. Mills,et al. Galectin‐3 is not useful in thyroid FNA , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.
[6] A. Miyauchi,et al. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. , 2005, Anticancer research.
[7] H. Nagaraja,et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors , 2005, Modern Pathology.
[8] S. Johnson,et al. Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasms , 2004, Histopathology.
[9] J. Sulkes,et al. Diagnostic value of galectin‐3 as a marker for malignancy in follicular patterned thyroid lesions , 2004, Head & neck.
[10] M. Papotti,et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid , 2004, Virchows Archiv.
[11] M. Papotti,et al. Galectin-3: Presurgical marker of thyroid follicular epithelial cell-derived carcinomas , 2004, Journal of endocrinological investigation.
[12] M. Miettinen,et al. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours , 1996, Virchows Archiv.
[13] R. Gaffney,et al. Galectin-3 Expression in Hyalinizing Trabecular Tumors of the Thyroid Gland , 2003, The American journal of surgical pathology.
[14] T. Koshikawa,et al. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. , 2003, Endocrine journal.
[15] J. Sygut,et al. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. , 2003, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[16] Z. Baloch,et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. , 2002, Archives of pathology & laboratory medicine.
[17] K. Mai,et al. Reduced HBME‐1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma‐related neoplastic lesions with Hürthle cell and/or apocrine‐like changes , 2002, Histopathology.
[18] E. Paal,et al. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature , 2001, Cancer.
[19] A. Longatto-Filho,et al. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas , 2001, Endocrine pathology.
[20] S. Natsugoe,et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. , 2000, Human pathology.
[21] M. P. Martegani,et al. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.